Avifavir For Treatment Of Patients With Moderate Coronavirus Disease 2019 (Covid-19): Interim Results Of A Phase Ii/Iii Multicenter Randomized Clinical Trial

Andrey A Ivashchenko, Kirill A Dmitriev,Natalia V Vostokova,Valeria N Azarova, Andrew A Blinow,Alina N Egorova,Ivan G Gordeev, Alexey P Ilin,Ruben N Karapetian,Dmitry V Kravchenko,Nikita V Lomakin,Elena A Merkulova, Natalia A Papazova, Elena P Pavlikova,Nikolay P Savchuk,Elena N Simakina, Tagir A Sitdekov,Elena A Smolyarchuk, Elena G Tikhomolova,Elena V Yakubova,Alexandre V Ivachtchenko

CLINICAL INFECTIOUS DISEASES（2021）

引用 212|浏览14

暂无评分

摘要

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated.

查看译文

关键词

AVIFAVIR, favipiravir, COVID-19, SARS-CoV-2

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要